Ye Dingwei

Specialized in comprehensive precision-based surgical treatment for urological and male reproductive system tumors—including prostate cancer, renal cell carcinoma, and bladder cancer—this approach leverages the anatomical characteristics of the Chinese population and over a thousand annual surgical cases to integrate the latest domestic and international therapeutic concepts. Through the innovative application of the "Dual-Tumor Resection Technique" combined with state-of-the-art robotic surgical systems for radical tumor resection, it maximizes the preservation of organ function while achieving a "dual high" outcome in both survival rate and quality of life for urological tumor patients.

Director of the Shanghai Institute of Urological Oncology; Director of the Prostate Cancer Research Institute at Fudan University; Chairman of the Male Reproductive System Oncology Committee of the Chinese Anti-Cancer Association (CACAGO); Chairman of the Prostate Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO); Chairman of the Urology Specialized Committee of the China Primary Health Care Foundation; Former Chairman of the Urological and Male Reproductive System Oncology Committee of the Chinese Anti-Cancer Association (CACAGU); Deputy Head of the Oncology Group of the Chinese Medical Association Urology Branch (CUA); Chairman of the China Prostate Cancer Alliance; Deputy Chairman of the Urinary Tract Carcinoma Expert Committee of the Chinese Society of Clinical Oncology (CSCO); Deputy Chairman of the Renal Cell Carcinoma Expert Committee of the Chinese Society of Clinical Oncology (CSCO); Deputy Chairman of the Immunotherapy Expert Committee of the Chinese Society of Clinical Oncology (CSCO); Chairman of the Urological Oncology Collaborative Group (UCOG) at the Chinese Cancer Hospital; Executive Council Member of the Chinese Anti-Cancer Association; Executive Council Member of the Chinese Society of Clinical Oncology; Member of the NCCN Asia Consensus Expert Committee on Diagnosis and Treatment of Prostate Cancer, Renal Cell Carcinoma, and Bladder Cancer; Member of the St. Gallen Consensus Expert Committee on Advanced Prostate Cancer; Chairman of the Urological Oncology Committee of the Shanghai Anti-Cancer Association; Vice President of the Urology Physician Branch of the Shanghai Medical Doctor Association; Former President of the Asian Pacific Prostate Society (APPS); Vice President of the Asian Pacific Society of Cryo-therapeutic Surgery; etc.

Has led more than 60 national and provincial/ministerial-level scientific research projects; published 704 papers (including 429 SCI-indexed papers); served as editor-in-chief or principal translator for 9 monographs; holds 38 invention patents. As the primary contributor, has been awarded two First Prizes of the Shanghai Municipal Science and Technology Progress Award, one First Prize and one Second Prize of the Ministry of Education Scientific and Technological Achievement Award, one First Prize of the Shanghai Medical Science and Technology Award, one Second Prize of the Chinese Medical Science and Technology Award, and one Second Prize of the China Anti-Cancer Association Science and Technology Award.

He is a nationally recognized mid-and young-level expert with outstanding contributions, honored by the Wu Jieping Urology Medical Award, the WuXi AppTec Life Sciences Research Award, the Shanghai Leading Talent Award, the Shanghai Outstanding Academic Discipline Leader Award, the Shanghai Craftsman Title, and the National Advanced Worker in the Health and Family Planning System Award; he also receives the Special Government Allowance from the State Council.